Astoria Biologica

Executive Summary

Astoria Biologica is a private biotechnology company headquartered in Boston, founded in 2019, with a focus on developing novel biologics and antibody-based therapeutics for autoimmune and inflammatory diseases, particularly Multiple Sclerosis. Leveraging advanced biologic platforms, the company aims to create targeted therapies that address significant unmet medical needs. While still in early stages with no disclosed pipeline milestones or funding history, Astoria Biologica operates in a competitive landscape of autoimmune therapeutics, where innovation in biologics offers potential for disease-modifying treatments. The company's private status and limited public information suggest it is likely in preclinical or early clinical development, requiring substantial capital and clinical validation to progress. Its Boston location provides access to a rich biotech ecosystem, including talent and potential partners.

Upcoming Catalysts (preview)

• Q4 2026Lead Candidate Enters Phase 1 Clinical Trial for Multiple Sclerosis30% success
• Q3 2026Completion of Series A Financing Round60% success
• Q2 2026Preclinical Data Presentation at Major Autoimmune Conference50% success